Targeting PKC‐mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia‐derived cell lines and blast cells
暂无分享,去创建一个
M. Konopleva | M. Andreeff | S. Kornblau | V. Ruvolo | T. Jiffar | J. Burks | P. Ruvolo | Liran Zhou | J. Watt | Peter P. Ruvolo
[1] A. Newton,et al. Protein kinase C: poised to signal. , 2010, American journal of physiology. Endocrinology and metabolism.
[2] D. Loegering,et al. Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation , 2009, The Journal of Biological Chemistry.
[3] G. Giaccone,et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Walling,et al. A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas , 2009, Clinical Cancer Research.
[5] J. McCubrey,et al. PKR Regulates B56α-mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells* , 2008, Journal of Biological Chemistry.
[6] A. Newton,et al. Spatiotemporal dynamics of lipid signaling: Protein kinase C as a paradigm , 2008, IUBMB life.
[7] A. LaCasce,et al. Enzastaurin , 2008, Expert opinion on investigational drugs.
[8] G. Bepler,et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Mackay,et al. Targeting the protein kinase C family: are we there yet? , 2008, Nature Reviews Cancer.
[10] A. Letai,et al. Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.
[11] J. Raemaekers,et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A. Redig,et al. Protein kinase C signalling in leukemia , 2008, Leukemia & lymphoma.
[13] A. Redig,et al. The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[14] R. Herbst,et al. Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer , 2007, Clinical Cancer Research.
[15] Y. Hannun,et al. Mechanism of Inhibition of Sequestration of Protein Kinase C α/βII by Ceramide , 2007, Journal of Biological Chemistry.
[16] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Kazanietz,et al. Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.
[18] John Calvin Reed,et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.
[19] Asim Khwaja,et al. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells , 2006, British journal of haematology.
[20] S. Corbalán-García,et al. Protein kinase C regulatory domains: the art of decoding many different signals in membranes. , 2006, Biochimica et biophysica acta.
[21] Z. Estrov,et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. , 2006, Blood.
[22] R. Campbell,et al. The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .
[23] E. Tran,et al. Direct Binding to Ceramide Activates Protein Kinase Cζ before the Formation of a Pro-apoptotic Complex with PAR-4 in Differentiating Stem Cells*[boxs] , 2005, Journal of Biological Chemistry.
[24] Steven M Kornblau,et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.
[25] Lisa L Gomez,et al. Critical Role for Protein Phosphatase 2A Heterotrimers in Mammalian Cell Survival* , 2004, Journal of Biological Chemistry.
[26] A. Fields,et al. Protein Kinase C (PKC) βII Induces Cell Invasion through a Ras/Mek-, PKCι/Rac 1-dependent Signaling Pathway* , 2004, Journal of Biological Chemistry.
[27] N. Underhill-Day,et al. Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCbetaII. , 2004, Cellular signalling.
[28] B. Teicher,et al. Antiangiogenic and Antitumor Effects of a Protein Kinase Cβ Inhibitor in Human Breast Cancer and Ovarian Cancer Xenografts , 2002, Investigational New Drugs.
[29] A. Davis,et al. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] E. Sausville,et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Harris,et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Kornblau,et al. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. , 2000, Journal of the National Cancer Institute. Monographs.
[33] F. Brembeck,et al. Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. , 2000, Journal of cell science.
[34] B. Calabretta,et al. BCR-ABL Prevents c-Jun-Mediated and Proteasome-Dependent FUS (TLS) Proteolysis through a Protein Kinase CβII-Dependent Pathway , 2000, Molecular and Cellular Biology.
[35] W. May,et al. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] T. Franke,et al. Protein kinase C-α overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal , 1999, Oncogene.
[37] J. McCubrey,et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs , 1999, Leukemia.
[38] T. Ito,et al. Ceramide Induces Bcl2 Dephosphorylation via a Mechanism Involving Mitochondrial PP2A* , 1999, The Journal of Biological Chemistry.
[39] A. Fields,et al. Overexpression of Protein Kinase C βII Induces Colonic Hyperproliferation and Increased Sensitivity to Colon Carcinogenesis , 1999, The Journal of cell biology.
[40] M. Mumby,et al. Reversible Phosphorylation of Bcl2 following Interleukin 3 or Bryostatin 1 Is Mediated by Direct Interaction with Protein Phosphatase 2A* , 1998, The Journal of Biological Chemistry.
[41] W. May,et al. A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis* , 1998, The Journal of Biological Chemistry.
[42] S. Korsmeyer,et al. Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.
[43] E. Friedman,et al. Protein kinase C beta 1 and protein kinase C beta 2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[44] D. Fabbro,et al. PKC zeta is a molecular switch in signal transduction of TNF‐alpha, bifunctionally regulated by ceramide and arachidonic acid. , 1995, The EMBO journal.
[45] P. G. Tyler,et al. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. , 1994, The Journal of biological chemistry.
[46] W. Farrar,et al. Altered cytosol/membrane enzyme redistribution on interleukin-3 activation of protein kinase C , 1985, Nature.
[47] Y Nishizuka,et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. , 1982, The Journal of biological chemistry.
[48] M. Menéndez-Gutiérrez,et al. Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. , 2007, The international journal of biochemistry & cell biology.
[49] Y. Hannun,et al. Mechanism of inhibition of sequestration of protein kinase C alpha/betaII by ceramide. Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/betaII on threonine 638/641. , 2007, The Journal of biological chemistry.
[50] M. Konopleva,et al. Bcl2 phosphorylation and active PKC α are associated with poor survival in AML , 2006, Leukemia.
[51] M. Konopleva,et al. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. , 2006, Leukemia.
[52] M. Konopleva,et al. PKC α mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation , 2004, Leukemia.
[53] A. Fields,et al. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. , 2004, The Journal of biological chemistry.
[54] Tadashi Honda,et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. , 2002, Blood.
[55] Beverly A. Teicher,et al. Antiangiogenic effects of a protein kinase Cβ-selective small molecule , 2001, Cancer Chemotherapy and Pharmacology.